stoxline Quote Chart Rank Option Currency Glossary
  
Nevro Corp. (NVRO)
5.72  -0.01 (-0.17%)    02-11 16:19
Open: 5.73
High: 5.73
Volume: 2,131,851
  
Pre. Close: 5.72
Low: 5.71
Market Cap: 217(M)
Technical analysis
2025-02-11 4:48:13 PM
Short term     
Mid term     
Targets 6-month :  6.77 1-year :  7.91
Resists First :  5.8 Second :  6.77
Pivot price 5.23
Supports First :  4.17 Second :  3.16
MAs MA(5) :  5.57 MA(20) :  5
MA(100) :  4.71 MA(250) :  8.07
MACD MACD :  0.3 Signal :  0.3
%K %D K(14,3) :  93.7 D(3) :  91.9
RSI RSI(14): 70.4
52-week High :  17.62 Low :  3.16
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ NVRO ] has closed below upper band by 9.7%. Bollinger Bands are 6.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.74 - 5.77 5.77 - 5.79
Low: 5.63 - 5.67 5.67 - 5.7
Close: 5.67 - 5.72 5.72 - 5.77
Company Description

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Headline News

Mon, 10 Feb 2025
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO - Business Wire

Mon, 10 Feb 2025
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders - Marketscreener.com

Mon, 10 Feb 2025
Jefferies Upgrades Nevro Corp (NVRO) to Hold - StreetInsider.com

Sat, 08 Feb 2025
Brokerages Set Nevro Corp. (NYSE:NVRO) PT at $6.30 - MarketBeat

Fri, 07 Feb 2025
Piper Sandler Upgrades Nevro (NVRO) - Nasdaq

Fri, 07 Feb 2025
Globus Medical to acquire Nevro for $5.85 per share - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 37 (M)
Shares Float 36 (M)
Held by Insiders 3.6 (%)
Held by Institutions 102 (%)
Shares Short 2,840 (K)
Shares Short P.Month 2,870 (K)
Stock Financials
EPS -1.88
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.3
Profit Margin -16.6 %
Operating Margin -15.7 %
Return on Assets (ttm) -9.1 %
Return on Equity (ttm) -24.8 %
Qtrly Rev. Growth -6.7 %
Gross Profit (p.s.) 7.6
Sales Per Share 11.18
EBITDA (p.s.) -1.96
Qtrly Earnings Growth 0 %
Operating Cash Flow -47 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -3.06
PEG Ratio 0
Price to Book value 0.78
Price to Sales 0.51
Price to Cash Flow -4.57
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android